NovoCure Ltd 8-K

What Happened

• On January 12, 2026, NovoCure Ltd filed an 8‑K (Item 2.02) and issued a press release announcing preliminary, unaudited financial results and other information for the quarter and year ended December 31, 2025. The company said the figures are based on good‑faith estimates and are subject to completion of its financial closing procedures; final results may differ materially. The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Date filed and released: January 12, 2026.
• Reporting period: quarter and year ended December 31, 2025.
• Nature of figures: unaudited, preliminary, based on management estimates and subject to closing procedures and final adjustments.
• Exhibit: Press Release is included as Exhibit 99.1; the 8‑K was signed by CFO Christoph Brackmann.

Why It Matters

• Preliminary results give investors an early look at NovoCure’s earnings and revenue trends for Q4 and full‑year 2025, but they are not final and may change after closing and audit procedures. Retail investors should treat these numbers as provisional and watch for the company’s final reported results and any adjustments in subsequent filings (e.g., Form 10‑K or quarterly reports) before making trading decisions.